Oculus Innovative Sciences Announces Reverse Split of Common Stock

Source:  Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced today that a 1-for-5 reverse split of its common stock will be effective after the close of business on Friday, June 24, 2016. The reverse stock split was previously approved by the company’s stockholders at the company’s special meeting held on June 29, 2015. The company’s board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-5 on June 2, 2016.  The reverse split was not the result of any NASDAQ actions. 

“Two years ago, we set out to change the strategic direction of our company with a new board of directors, new management team and new strategic direction focusing on the U.S. dermatology market with our own direct sales force. Since then, we've shown measurable progress resulting in growth in U.S. revenue of 123% for the last twelve months," said Jim Schutz, Oculus CEO. "Now that we've demonstrated that our restructuring plan is bearing fruit with strong sales of our seven prescription products and fast revenue growth, our next steps are to change the name of the company in the upcoming months to more accurately reflect our focus on dermatology, and second, to proactively execute a reverse split to position our stock price to be attractive to larger investors, closer to the $5 per share investment grade target.  We believe that the combination of a higher stock price and the continued success of our dermatology strategy with quarterly new product launches and a growing sales force of over 20 will be attractive to a new level of investors and help propel Oculus forward."

At the effective time of the reverse stock split, every five shares of Oculus’ issued and outstanding common stock will be automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share.  All fractional shares will be paid an amount equal to the product obtained by multiplying (a) the closing price per share of the common stock as reported on the NASDAQ Capital Market as of the date of the effective date, by (b) the fraction of one share owned by stockholder.

The reverse stock split will reduce the number of shares of Oculus’ common stock outstanding from 21 million to approximately 4.2 million.  The number of authorized shares of the company’s common stock will also be proportionally reduced from 60 million to 12 million. Proportional adjustments will be made to Oculus’ stock options, warrants and equity-compensation plans.  The reverse stock split will have no effect on the company’s authorized shares of preferred stock.

The company’s common stock will continue to trade on The NASDAQ Capital Market under the symbol “OCLS” until such time a corporate name change is implemented. A new CUSIP number will be assigned to Oculus’ common stock after the reverse stock split becomes effective.

The reverse stock split is intended to increase the per share trading price of the company’s ordinary shares to both satisfy the $1.00 minimum bid price requirement on The NASDAQ Capital Market and to encourage the trading of Oculus shares by institutional funds that typically pass on stocks that are priced less than $5.00 per share.

Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account will have their shares automatically adjusted to the reflect the 1-for-5 reverse stock split.  Existing stockholders holding common stock certificates will receive a letter of transmittal from the company’s transfer agent, Computershare, Inc. with specific instructions regarding the exchange of shares.

About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com